Literature DB >> 19662428

Botox injection treatment for anal outlet obstruction in patients with internal anal sphincter achalasia and Hirschsprung's disease.

A I Koivusalo1, M P Pakarinen, R J Rintala.   

Abstract

BACKGROUND AND AIM: Botox injection treatment (BIT) is a potentially effective but yet unproven treatment of functional anal outlet obstruction that is caused by non-relaxing internal anal sphincter. We present a single institution experience of BIT from 2005 to 2008. PATIENTS AND METHODS: Sixteen patients (11 males), eight with Hirschsprung's disease (HD) (one with total colon aganglionosis, TCA) and eight with internal sphincter achalasia (ISA) were included. Median ages were 3.8 years (0.4-9.3) for HD and 8.1 years (range 1.5-11.4) for ISA. ISA was defined as the absence of rectoanal inhibitory reflex with normal rectal biopsies. Seven HD patients had previous coloanal pull-through (CAPT), and one (TCA) colectomy and ileoanal J-Pouch anastomosis. Two of the ISA patients had undergone internal sphincter myectomy and two had Malone procedure [antegrade colonic enema (ACE)]. Indication for BIT in 16 patients was anal outlet obstruction (n = 11) with soiling and recurring HD-associated enterocolitis (n = 5) and in one patient (HD, TCA) soiling with enterocolitis (n = 1). Before BIT, all patients underwent anorectal manometry, rectal biopsies and barium enema. The effect of BIT was evaluated after 2 months and BIT was repeated if necessary. Effect of BIT was scored as follows: 0 no, 1 little, 2 significant effect and 3 symptoms disappeared.
RESULTS: Median follow-up was 19 months (range 3-43). The median number of injections was two per patient (range 1-4) and the median Botox dose was 80 U (range 40-100). Scores of BIT effect were 3 or 2 in five (31%) and 0 or 1 in 11 (69%). After adjunctive treatment modalities (myectomy n = 1, CAPT n = 1, adjusted ACE/laxative treatment), the end result was good or satisfactory in 11 (69%) but remained poor in 5 (31%) patients. Patient age, diagnosis, anorectal resting pressure or findings in barium enema were not correlated with BIT efficiency score (R range -0.06 to 0.39, P = 0.12-0.91).
CONCLUSION: Although successful in some patients, the role of BIT remains undetermined. It is difficult to predict which patients will profit from BIT. Continuing other treatment modalities after BIT may improve the results.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19662428     DOI: 10.1007/s00383-009-2438-3

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  9 in total

Review 1.  Posterior myotomy/myectomy for persistent stooling problems in Hirschsprung's disease.

Authors:  Barbara E Wildhaber; Mikko Pakarinen; Risto J Rintala; Arnold G Coran; Daniel H Teitelbaum
Journal:  J Pediatr Surg       Date:  2004-06       Impact factor: 2.545

2.  Long-term outcome after internal sphincter myectomy for internal sphincter achalasia.

Authors:  M Heikkinen; H Lindahl; R J Rintala
Journal:  Pediatr Surg Int       Date:  2004-12-23       Impact factor: 1.827

3.  The treatment of internal anal sphincter achalasia with botulinum toxin.

Authors:  A Messineo; D Codrich; M Monai; S Martellossi; A Ventura
Journal:  Pediatr Surg Int       Date:  2001-09       Impact factor: 1.827

4.  Botulinum toxin for the treatment of chronic constipation in children with internal anal sphincter dysfunction.

Authors:  Katy Irani; Leonel Rodriguez; Daniel P Doody; Allan M Goldstein
Journal:  Pediatr Surg Int       Date:  2008-04-29       Impact factor: 1.827

5.  Anorectal manometric evaluation of children and adolescents postsurgery for Hirschsprung's disease.

Authors:  Carlos Zaslavsky; Vera Loening-Baucke
Journal:  J Pediatr Surg       Date:  2003-02       Impact factor: 2.545

6.  Persistent obstructive symptoms after surgery for Hirschsprung's disease: development of a diagnostic and therapeutic algorithm.

Authors:  Jacob C Langer
Journal:  J Pediatr Surg       Date:  2004-10       Impact factor: 2.545

7.  Role of rectal biopsy in predicting response to intrasphincteric botulinum toxin injection for obstructive symptoms after a pullthrough operation.

Authors:  Seyed Mohammad Vahid Hosseini; Hamid Reza Foroutan; Ali Bahador; Mohammad Bagher Khosravi; Bita Geramizadeh; Babak Sabet; Sam Zeraatian; Tannaz Razmi; Seyed Javad Banani
Journal:  Indian J Gastroenterol       Date:  2008 May-Jun

8.  Internal anal sphincter achalasia in children: clinical characteristics and treatment with Clostridium botulinum toxin.

Authors:  Paola Ciamarra; Samuel Nurko; Edward Barksdale; Steven Fishman; Carlo Di Lorenzo
Journal:  J Pediatr Gastroenterol Nutr       Date:  2003-09       Impact factor: 2.839

9.  Long-term clinical outcome after botulinum toxin injection in children with nonrelaxing internal anal sphincter.

Authors:  Bruno P Chumpitazi; Steven J Fishman; Samuel Nurko
Journal:  Am J Gastroenterol       Date:  2009-03-03       Impact factor: 10.864

  9 in total
  8 in total

Review 1.  Recent developments in Hirschsprung's-associated enterocolitis.

Authors:  Elizabeth M Pontarelli; Henri R Ford; Christopher P Gayer
Journal:  Curr Gastroenterol Rep       Date:  2013-08

Review 2.  Classification and diagnostic criteria of variants of Hirschsprung's disease.

Authors:  Florian Friedmacher; Prem Puri
Journal:  Pediatr Surg Int       Date:  2013-09       Impact factor: 1.827

3.  Comparison of posterior internal anal sphincter myectomy and intrasphincteric botulinum toxin injection for treatment of internal anal sphincter achalasia: a meta-analysis.

Authors:  Florian Friedmacher; Prem Puri
Journal:  Pediatr Surg Int       Date:  2012-08       Impact factor: 1.827

4.  Botulinum toxin is efficient to treat obstructive symptoms in children with Hirschsprung disease.

Authors:  Tomas Wester; Anna Löf Granström
Journal:  Pediatr Surg Int       Date:  2015-01-24       Impact factor: 1.827

5.  Botulinum toxin use in paediatric colorectal surgery.

Authors:  S Basson; P Charlesworth; C Healy; S Phelps; Stewart Cleeve
Journal:  Pediatr Surg Int       Date:  2014-07-06       Impact factor: 1.827

Review 6.  Hirschsprung-associated enterocolitis: prevention and therapy.

Authors:  Philip K Frykman; Scott S Short
Journal:  Semin Pediatr Surg       Date:  2012-11       Impact factor: 2.754

Review 7.  ERNICA guidelines for the management of rectosigmoid Hirschsprung's disease.

Authors:  Kristiina Kyrklund; Cornelius E J Sloots; Ivo de Blaauw; Kristin Bjørnland; Udo Rolle; Duccio Cavalieri; Paola Francalanci; Fabio Fusaro; Annette Lemli; Nicole Schwarzer; Francesco Fascetti-Leon; Nikhil Thapar; Lars Søndergaard Johansen; Dominique Berrebi; Jean-Pierre Hugot; Célia Crétolle; Alice S Brooks; Robert M Hofstra; Tomas Wester; Mikko P Pakarinen
Journal:  Orphanet J Rare Dis       Date:  2020-06-25       Impact factor: 4.123

8.  Botulinum toxin injection for internal anal sphincter achalasia after pull-through surgery in Hirschsprung disease.

Authors:  Joong Kee Youn; Ji-Won Han; Chaeyoun Oh; So-Young Kim; Sung-Eun Jung; Hyun-Young Kim
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.